中国最著名的加密货币狂热者:“我将动用全部资产购买这种山寨币”

cryptonews.ruPublished on 2026-08-23Last updated on 2026-08-23

Abstract

中国知名加密货币矿工江卓尔(BTC.TOP创始人)近期修正观点,认为加密货币熊市或已结束,并高度看好以太坊(ETH)走势。他透露已在1738至1931美元区间回购此前卖出的ETH,并设置2100美元止损单;随后以2525美元卖出50%现货ETH,同时设2550美元止损以尝试捕捉市场顶部。 江卓尔计划动用20–30%的未投放储备资金购买以太坊。他表示,若比特币跌至6.7万至7.2万美元区间,将动用剩余资金买入ETH;若未跌至此区间,则会在10月底前按市价完成对ETH的投入,这意味着其将把全部剩余储备投入以太坊。 他同时指出,加密货币市场已进入稳定上涨趋势,精准预测市场顶部的难度较大。

江卓尔,中国最著名的加密货币矿工之一,也是 $BTC.TOP 的创始人,他极大地强化了关于市场可能已见底的观点,并承认自己此前关于熊市的预测大体上是错误的。江表示,他现在有90%的把握认为熊市已经结束,并且以太坊 ($ETH) 在本轮周期中可能表现优于比特币 ($BTC)。

江卓尔解释称,他已经以1738到1931美元的价格买回了此前卖出的 $ETH,并在2100美元位置设置了止损单。随后他表示,自己以2525美元的价格卖出了其持有的50%现货 $ETH,试图预测市场顶部,并为这笔交易在2550美元处设置了止损单。

这位知名矿工声称,计划动用大约20-30%尚未投放市场的储备金来购买以太坊。据江卓尔所说,如果比特币价格跌至67,000–72,000美元区间,剩余资金将被用于购买 $ETH

如果比特币没有跌至这些水平,江卓尔则表示,他最晚将在十月底前以当前市价买入以太坊。这表明了他计划将全部剩余储备金投资于 $ETH 的意图。

江卓尔还表示,加密货币市场正显示出持续的上升趋势,因此准确预测市场顶部的可能性相对较低。

*本文不构成投资建议。

end-content

Trending Cryptos

Related Questions

Q江卓尔对自己之前的市场预测做出了怎样的修正?

A江卓尔修正了之前的观点,承认之前的看跌市场预测在很大程度上是错误的,并表示他现在有90%的把握认为熊市已经结束。

Q江卓尔对以太坊(ETH)和比特币(BTC)在当前周期的表现有什么看法?

A江卓尔认为,在当前市场周期中,以太坊(ETH)的表现可能会超过比特币(BTC)。

Q江卓尔计划如何分配他尚未投入市场的备用资金来购买以太坊?

A江卓尔计划使用大约20-30%的尚未投入市场的备用资金来购买以太坊(ETH)。

Q江卓尔设定了什么条件,才会用剩余的全部资金购买以太坊?

A江卓尔表示,如果比特币(BTC)价格跌至67,000至72,000美元区间,他将用剩余的备用资金全部购买以太坊(ETH)。

Q如果比特币价格没有跌到他设定的区间,江卓尔计划何时购买以太坊?

A如果比特币价格没有跌至67,000-72,000美元区间,江卓尔计划最晚在十月底之前按当前市价购买以太坊(ETH),这等于他将把所有剩余备用资金投入ETH。

Related Reads

Three Months After the Passing of Little Dog Rosie, Her Medical Records Transformed into an AI Healthcare Company

Three months after the passing of his dog Rosie, AI entrepreneur Paul S. Conyngham secured $4 million in seed funding from Founders Fund for his new startup, Gamgee. The company aims to industrialize the experimental, AI-assisted process he pioneered to create a personalized mRNA cancer vaccine for Rosie, who suffered from mast cell tumors. With no formal biology background, Conyngham used AI tools like ChatGPT and AlphaFold to analyze Rosie's tumor DNA, identify target neoantigens, and design a custom mRNA vaccine sequence. Laboratory partners at UNSW produced the vaccine. Initial treatment showed tumor reduction, but Rosie's cancer later recurred and she was euthanized. Gamgee's goal is to streamline this "N-of-1" approach into a repeatable service for canine cancer patients, handling sequencing, vaccine design, production, and delivery. Clinical trials are planned in Australia in collaboration with research institutions. The company also eyes a longer-term vision of establishing personalized, mRNA-based medicine across species. The story highlights the broader challenge in personalized cancer treatment: compressing the entire timeline from design and regulatory approval to manufacturing and administration to match the patient's prognosis. While AI can accelerate target discovery, the remaining logistical and regulatory hurdles are significant. The article concludes by emphasizing that, for now, consulting qualified veterinary oncologists remains the responsible path for pet owners.

marsbit5m ago

Three Months After the Passing of Little Dog Rosie, Her Medical Records Transformed into an AI Healthcare Company

marsbit5m ago

mRNA Vaccine Too Slow, Dog Owner Loses Beloved Pet, World's First AI-Customized Dog Cancer Vaccine Arrives

A heartbreaking story from Australia showcases the intersection of AI, love, and loss. Paul Conyngham, an AI expert, lost his beloved bull terrier Rosie to cancer in 2024. Refusing to accept her prognosis, he used his machine learning skills, ChatGPT, and AlphaFold to design a personalized mRNA vaccine targeting her specific cancer mutations. The first vaccine dose, synthesized with help from university scientists, shrank Rosie's tumor by 75%, granting her a temporary reprieve. However, the cancer recurred with new mutations, requiring a second, updated vaccine. The traditional, slow production process couldn't deliver it in time, and Rosie passed away. Determined to prevent similar tragedies, Paul founded Gamgee, a startup named after a "Lord of the Rings" character. Backed by $4 million in seed funding from Founders Fund, Y Combinator, and others, Gamgee aims to industrialize and democratize personalized canine cancer vaccines. Their vision is an end-to-end platform where veterinarians submit tumor samples, AI algorithms rapidly identify target mutations, and customized mRNA vaccines are produced. The goal is to slash the design time to 48 hours and the total cost to around $2,000 per treatment. The addressable market is vast, with about 6 million dogs diagnosed with cancer annually in the US alone. Beyond pets, Gamgee's "N-of-1" medicine approach, validated in dogs, paves the way for similar ultra-personalized cancer therapies for humans, a field recently energized by Moderna's successful AI-designed mRNA vaccine trial for melanoma. Rosie's legacy lives on, fueling a mission to turn personalized hope into scalable, timely reality for millions.

marsbit9m ago

mRNA Vaccine Too Slow, Dog Owner Loses Beloved Pet, World's First AI-Customized Dog Cancer Vaccine Arrives

marsbit9m ago

Not Being a Follower of Silicon Valley: A Few Young PhD Students Bet on the Integrated Brain of Bipedal Humanoid Robots

This article profiles GongShengZhiXing, a startup founded by 1996-born Ding Pengxiang with a core team of Ph.D. students, all in their twenties. They are developing an end-to-end, integrated "brain" (base model) for bipedal humanoid robots, focusing on full-body dynamic coordination rather than the industry's more common modular, layered approach. The team's stance is that for humanoids to integrate into human environments, an end-to-end model—where a single system handles perception, decision-making, and control directly—is ultimately more efficient and scalable than layered architectures that separate high-level "brain" and low-level "cerebellum" functions. They argue layered systems create information bottlenecks. A key demo shows their robot driving a go-kart at high speed, demonstrating synchronized hand-eye-foot coordination and multi-contact balance—a complex task highlighting their focus on whole-body dynamics over simple kinematics. Technically, their model outputs commands at the joint level and incorporates a "Motion Expert" module and techniques like DriftDistill to simultaneously learn task completion and physical stability from data. Acknowledging challenges like severe data scarcity for full-body mobile manipulation, they employ methods like TrajBooster to synthesize training data. Ding Pengxiang believes true "emergence" of new skills at the joint-movement level is the goal, but commercial viability likely requires scaling to millions of training hours. The team aims not to follow Silicon Valley trends but to pioneer and potentially set global standards in this nascent, unconverged field of embodied AI.

marsbit10m ago

Not Being a Follower of Silicon Valley: A Few Young PhD Students Bet on the Integrated Brain of Bipedal Humanoid Robots

marsbit10m ago

Trading

Spot

Hot Articles

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of S (S) are presented below.

活动图片